Welcome to the e-CCO Library!

P684: Vaccination strategies for IBD patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Sitibondo*1, A. Squeri1, A. Viola1, G. Costantino1, A. Belvedere1, V. Pisana1, F. Costa2, R. Squeri2, W. Fries1

Created: Friday, 22 February 2019, 9:41 AM
P685 Healthcare resource use associated with ferric maltol and IV iron treatment for iron deficiency anaemia in patients with inflammatory bowel disease
Year: 2020
Source: ECCO'20 Vienna
Authors: S. Howaldt1, I. Jacob2, M. Sampson3, F. Akriche4
Created: Thursday, 30 January 2020, 10:12 AM
Last Modified: Wednesday, 3 March 2021, 4:11 PM by Dauren Ramankulov

Corrigendum:

In the originally published version of this poster presentation, the below corrections have been made.

Upon the original publication, the following sentence in Results section should read: “The primary endpoint was not met.” instead of “The non-inferiority endpoint was met.”.

Upon the original publication, the final concluding remarks should read: “FM is associated with substantially lower HCRU than IV FCM, and may provide a cost-effective oral alternative to IV iron in patients with IBD.” instead of “FM is associated with non-inferior efficacy and substantially lower HCRU than IV FCM, and may provide a cost-effective oral alternative to IV iron in patients with IBD.”.

P685: Early use of infliximab after seton technique for patients with Crohn's disease who initially presented with perianal fistulas
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lim, K.Y.(1)*;Hwang, D.Y.(1);Lee, J.K.(1);
Created: Friday, 14 July 2023, 11:12 AM
P685: Gut microbiota in patients with Inflammatory Bowel Disease during remission
Year: 2021
Source: ECCO'21 Virtual
Authors: Pisani, A.(1);Rausch, P.(2);Ellul, S.(3);Bang, C.(2);Tabone, T.(1);Marantidis Cordina, C.(4);Zahra, G.(5);Ellul, P.(1);Franke, A.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P685: Improvement in patient-reported Inflammatory Bowel Disease Questionnaire outcomes, and relationship with disease activity, in tofacitinib-treated patients with ulcerative colitis: Data from the OCTAVE clinical trials
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. C. Dubinsky1, B. Bressler2, A. Armuzzi*3, L. Salese4, M. DiBonaventura5, E. Maller4, H. Fan4, D. A. Woodworth4, C. Su4

Created: Friday, 22 February 2019, 9:41 AM
P685: Patient’s performance and feedback by using home test faecal calprotectin as an objective reported outcome
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.C. Wei*

Created: Thursday, 21 February 2019, 9:14 AM
P685: Strong Response to SARS-CoV-2 Vaccine Additional Doses among Patients with Inflammatory Bowel Diseases
Year: 2022
Source: ECCO'22
Authors: Kappelman, M.(1);Weaver, K.(2);Zhang, X.(1);Chun, K.(3);Long, M.(2);
Created: Friday, 11 February 2022, 3:56 PM
P685: Switching from originator-infliximab to biosimilar-infliximab has no influence on health-related quality of life and clinical disease activity among patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Huoponen S.*1, Eberl A.1,2, Räsänen P.1,2, Roine R.P.2,3, Sipponen T.1,2, Arkkila P.1,2, Blom M.1

Created: Wednesday, 20 February 2019, 10:36 AM
P686 Expression of CD39 ectonucleotidase on regulatory T cells and on T helper 17 cells in children with IBD receiving anti-TNF therapy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S.V. Petrichuk1, Т. Radygina1, A. Illarionov2, D. Kuptsova1, A. Potapov3, A.P. Fisenko3

Created: Thursday, 30 January 2020, 10:12 AM
P686: Application of dried blood spots for pharmacokinetic profiling of golimumab-treated patients with ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Detrez I.*1, Ballet V.2, Van Assche G.2, Vermeire S.2, Ferrante M.2, Gils A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P686: Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: PRACTICROHN study
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Barreiro-de Acosta1*, V. García2, A. Gutiérrez3, M.D. Martín Arranz4, M. Iborra5, C. Taxonera6, C. Romero7, B. Juliá7, L. Cea-Calvo7, E. Domènech8

Created: Thursday, 21 February 2019, 9:14 AM
P686: Neither high infliximab maintenance doses nor high trough levels trigger skin side effects of the drug: a prospective cross-sectional study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Kurent*1, U. Koren2, J. Hanzel1, M. Kozelj1, G. Novak1, N. Smrekar1, B. Stabuc1, N. Kecelj3, D. Drobne1

Created: Friday, 22 February 2019, 9:41 AM
P686: Novel grape-derived prebiotic selectively enhances abundance and metabolic activity of IBD and IBS faecal butyrate producing bacteria in an in vitro model of intestinal fermentation
Year: 2021
Source: ECCO'21 Virtual
Authors: Oliver, L.(1);Ramió-Pujol, S.(1);Amoedo, J.(1);Malagón, M.(1);Serrano, M.(1);Bahí, A.(2);Lluansí, A.(2);Busquets, D.(3);Pardo, L.(3);Serra-Pagès, M.(1);Aldeguer, X.(3);Garcia-Gil, J.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P686: Outcomes of COVID-19 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study
Year: 2022
Source: ECCO'22
Authors: Attauabi, M.(1,2,3);Dahlerup, J.F.(4);Poulsen, A.(5);Rosager Hansen, M.(6);Vester-Andersen, M.K.(7);Eraslan, S.(3);Prahm, A.P.(5);Pedersen, N.(8);Larsen, L.(9);Jess, T.(9,10);Neumann, A.(11);Haderslev, K.V.(12);Molazahi, A.(13);Lødrup, A.B.(14);Glerup, H.(15);Oppfeldt, A.M.(16);Jensen, M.D.(17);Theede, K.(1,2);Kiszka-Kanowitz, M.(1,2);Seidelin, J.B.(3);Burisch, J.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P687 Early and sustained improvement in stool frequency and rectal bleeding following 52 weeks of mirikizumab treatment
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G.R. D’Haens1, T. Hibi2, M. Ferrante3, B.R. Bhandari4, E. Berliba5, J.L. Tuttle6, T. Lissoos7, K. Krueger7, N. Morris7, V. Arora7, A.N. Naegeli7, B.G. Feagan8

Created: Thursday, 30 January 2020, 10:12 AM
P687: Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. G. Feagan*1, W. J. Sandborn2, G. D'Haens3, S. Hanauer4, D. C. Wolf5, S. Vermeire6, S. Ghosh7, A. Petersen8, S. Y. Hua8, K. Shan8, J. Liu8

Created: Friday, 22 February 2019, 9:41 AM
P687: Development of a panel of microbial markers to distinguish transient from pathological dysbiosis
Year: 2021
Source: ECCO'21 Virtual
Authors: Oliver, L.(1);Ramió-Pujol, S.(1);Malagón, M.(1);Serrano, M.(1);Bahí, A.(2);Busquets, D.(3);Torrealba, L.(3);Serra-Pagès, M.(1);Aldeguer, X.(3);Garcia-Gil, J.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P687: Durability of recaptured response to ozanimod during the True North open-label extension
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dignass, A.(1)*;Regueiro, M.(2);Colombel, J.F.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Vermeire, S.(5);Rubin, D.T.(6);
Created: Friday, 14 July 2023, 11:12 AM
P687: Fate of the rectum in anorectal Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zambonin D., Scaringi S., Di Bella A., Giudici F., Bechi P.

Created: Wednesday, 20 February 2019, 10:36 AM
P687: Female sex is associated with discontinuation of subcutaneous anti-TNF therapy for side effects in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Schultheiss*, E. Lamers, E. Brand, H. Fidder

Created: Thursday, 21 February 2019, 9:14 AM